Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?

Kok Hoon Tay; Deirdre A. Lane; Gregory Y. H. Lip

doi:10.1160/TH08-10-0685

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(06): 955-957
DOI: 10.1160/TH08-10-0685

Editorial Focus

Schattauer GmbH

Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?

Kok Hoon Tay

¹Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom

,

Deirdre A. Lane

¹Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom

,

Gregory Y. H. Lip

¹Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom

› Author Affiliations

Abstract

PDF Download

PDF (197 kb)

References

References
1 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
2 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
3 McBane RD, Hodge DO, Wysokinski WE. Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation. Thromb Haemost 2008; 99: 951-955.
4 May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
5 Johnson SG, Witt DM, Eddy TR. et al. Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 2007; 131: 1500-1507.
6 Shireman TI, Howard PA, Kresowik TF. et al. Combined anticoagulation-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35: 2362-2367.
7 Lechat P, Lardoux H, Mallet A. et al. Anticoagulant (fluindione)-aspirin combination in patients with highrisk atrial fibrillation: a randomized trial (Fluindione, Fibrillation, Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis 2001; 12: 245-252.
8 Flaker GC, Gruber M, Connolly SJ. et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrialfibrillation (SPORTIF) trials. Am Heart J 2006; 152: 967-973.
9 Lip GYH. Don’t add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. Br Med J 2008; 336: 614-615.
10 Fuster V, Ryden LE, Cannom Ds. et al. ACC/AHA/ ESC 2006 guideline for the management of patients with atrialfibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of patients with Atrial Fibrillation). Circulation 2006; 114: 257-354.
11 Rubboli A, Halperin JL, Juhani Airaksinen KE. et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40: 428-436.
12 Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: The need for consensus and a management guideline. Chest 2006; 130: 1823-1827.
13 Schalekamp T, Klungel O, Souverein P. et al. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008; 100: 1076-1083.
14 Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Therap 2004; 26: 1470-1478.
15 Wehinger C, Stöllberger C, Länger T. et al. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32: 2246-2252.
16 Fang MC, Go AS, Hylek EM. et al. Age and the risk of warfarin associated-haemorrhage: The anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54: 1231-1236.
17 Hughes M, Lip GYH. Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007 100. 599-607.
18 Fang MC, Go AS, Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial haemorrhages. AmJ Med 2007; 120: 700-705.
19 Kuijer PMM, Hutten BA, Prins MH. et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
20 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
21 Gage BF, Yan Y, Milligan PE. et al. Clinical classification schemes for predicting haemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am HeartJ 2006; 151: 713-719.
22 Shireman TI, Mahnken JD, Howard PA. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130: 1390-1396.